Swimming the political sea with the US FDA: A fine kettle of fish?
This article was originally published in SRA
What played out in the US on Capitol Hill in the aftermath of the September 2004 withdrawal from the worldwide market of Merck's Vioxx (rofecoxib) - with regulators being frequently hauled in front of congressional committees - is probably the best evidence the US Food and Drug Administration is often at the mercy of political and societal pressures.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.